5 Key Takeaways

• 1

  The TEASE program evaluates gildeuretinol's efficacy in reducing atrophic lesion growth in Stargardt disease.

• 2

  Gildeuretinol reduces toxic vitamin A dimerization by up to 80% and is metabolized like vitamin A.

• 3

  TEASE-1 and TEASE-2 trials demonstrated significant reductions in lesion growth and EZ loss in Stargardt patients.

• 4

  The ongoing NORTHSTAR phase 3 trial aims to assess gildeuretinol's safety and efficacy in advanced Stargardt disease.

• 5

  Gildeuretinol has shown mild to moderate tolerability with no significant safety signals reported in the studies.